[1]崔建坤.莫西沙星序贯治疗老年社区获得性肺炎效果及对肺功能的影响[J].医学信息,2021,34(08):147-149.[doi:10.3969/j.issn.1006-1959.2021.08.039]
　CUI Jian-kun.Effect of Moxifloxacin Sequential Treatment of Elderly Community Acquired Pneumonia and Its Influence on Lung Function[J].Medical Information,2021,34(08):147-149.[doi:10.3969/j.issn.1006-1959.2021.08.039]
点击复制

莫西沙星序贯治疗老年社区获得性肺炎效果及对肺功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年08期
页码:
147-149
栏目:
药物与临床
出版日期:
2021-04-15

文章信息/Info

Title:
Effect of Moxifloxacin Sequential Treatment of Elderly Community Acquired Pneumonia and Its Influence on Lung Function
文章编号:
1006-1959（2021）08-0147-03
作者:
崔建坤
（天津市黄河医院呼吸消化科，天津 300110）
Author(s):
CUI Jian-kun
(Department of Respiratory and Gastroenterology,Tianjin Huanghe Hospital,Tianjin 300110,China)
关键词:
莫西沙星; 社区获得性肺炎; 肺功能
Keywords:
Moxifloxacin; Community acquired pneumonia; Lung function
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2021.08.039
文献标志码:
A
摘要:
目的 研究莫西沙星序贯治疗对老年社区获得性肺炎效果及对肺功能的影响。方法 选取2018年2月~2020年2月我院治疗的100例老年社区获得性肺炎患者为研究对象，采用随机数字表法分为对照组和观察组，各50例。对照组采用莫西沙星静滴治疗，观察组采用莫西沙星序贯治疗，比较两组临床治疗效果、肺功能指标、临床症状评分、炎症指标以及临床不良反应发生情况。结果 观察组治疗总有效率为96.00%，高于对照组的84.00%，差异有统计学意义（P＜0.05）；观察组FEV1、FVC、FEV1/FVC高于对照组，差异有统计学意义（P＜0.05）；观察组咳嗽、咳痰、起初、肺部湿啰因评分低于对照组，差异有统计学意义（P＜0.05）；观察组WBC、CRP水平对照组，差异有统计学意义（P＜0.05）；观察组不良反应发生率为6.00%，低于对照组的14.00%，差异有统计学意义（P＜0.05）。结论 莫西沙星序贯治疗老年社区获得性肺炎效果可提高总有效率，改善肺功能指标，降低临床症状评分和炎症因子水平，且临床不良反应发生率低，具有确切的应用有效性和安全性。
Abstract:
Objective To study the effect of moxifloxacin sequential treatment on elderly community-acquired pneumonia and its influence on lung function.Methods A total of 100 elderly patients with community-acquired pneumonia treated in our hospital from February 2018 to February 2020 were selected as the research objects. They were divided into a control group and an observation group by random number table method, with 50 cases in each.The control group was treated with moxifloxacin intravenously, and the observation group was treated with moxifloxacin sequential. The clinical treatment effects, pulmonary function indexes, clinical symptom scores, inflammation indexes, and occurrence of clinical adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 96.00%, which was higher than 84.00% in the control group,the difference was statistically significant (P<0.05);The FEV1, FVC, FEV1/FVC of the observation group were higher than those of the control group,the difference was statistically significant (P＜0.05);The observation group’s cough, sputum, initial, and lung wetness scores were lower than those of the control group,the difference was statistically significant (P<0.05);The observation group WBC, CRP level control group, the difference was statistically significant (P<0.05);The incidence of adverse reactions in the observation group was 6.00%, which was lower than 14.00% in the control group,the difference was statistically significant(P<0.05).Conclusion Moxifloxacin sequential treatment of community-acquired pneumonia in the elderly can increase the total effective rate, improve lung function indicators, reduce clinical symptom scores and inflammatory factor levels, and have a low incidence of clinical adverse reactions. It has definite application effectiveness and safety.

参考文献/References:

[1]郭亚岚,詹继东.莫西沙星联合头孢哌酮他唑巴坦治疗老年社区获得性肺炎疗效观察[J].中国社区医师,2019,35(7):31-32. [2]亓慧琴.莫西沙星序贯治疗老年社区获得性肺炎的临床评价[D].吉林大学,2018. [3]Prina E,Ranzani OT,Torres A.Community-acquired pneumonia[J].Lancet,2015(386):1097-1108. [4]王晓航.左氧氟沙星与莫西沙星对老年社区获得性肺炎患者临床治疗的有效性比较[J].抗感染药学,2020,90(1):128-131. [5]Morimoto K,Suzuki M,Ishifuji T,et al.The Burden and Etiology of Community-acquried Pneumonia in the Aging Japanese Population:A Multicenter Prospective Study[J].PLoS One,2015,10(3):e0122247. [6]张先明,唐凤婕,杜丹,等.贵阳地区社区获得性肺炎诊治现状与中国指南对比研究[J].中国全科医学,2015,18(5):521-524. [7]韩瑛，张丽.莫西沙星与左氧氟沙星对2 型糖尿病合并社区获得性肺炎血清炎症因子的研究[J].山西医药杂志,2018,47(23):2863-2865. [8]徐意,朱峰,黄振荣.莫西沙星对老年社区获得性肺炎患者抗感染疗效及肺功能的影响[J].中华医院感染学杂志,2018,28(4):485-487. [9]张继翱,李家瑞,张宇．社区获得性肺炎抗菌药物治疗的临床观察[J].中华医院感染学杂志,2014,24(2):347-348． [10]单毅．莫西沙星静脉滴注联合口服序贯治疗老年社区获得性肺炎临床观察[J].解放军医药杂志,2015,27(10):88-90． [11]段艳红,杜春玲.莫西沙星治疗高龄社区获得性肺炎临床研究[J].临床肺科杂志,2016,21(5):841-844． [12]刘宪军.1824例莫西沙星不良反应报告分析[J].中国药业,2015,24(13):56-58． [13]吴坚,付瑛.盐酸莫西沙星注射液对社区获得性肺炎患者的治疗效果[J].医疗装备,2016,29(16):118-119． [14]赖雁威．盐酸莫西沙星与头孢地尼治疗社区获得性肺炎的临床疗效观察[J].现代诊断与治疗,2015,26(14):3184-3185． [15]赵珊.莫西沙星与左氧氟沙星序贯治疗老年社区获得性肺炎的疗效观察[J].中国药业,2018,16(6):73-75.

相似文献/References:

[1]赵建美,邵 岩.血必净治疗社区获得性肺炎的研究进展[J].医学信息,2018,31(02):20.[doi:10.3969/j.issn.1006-1959.2018.02.009]
　ZHAO Jian-mei,SHAO Yan.Research Progress of Xuebijing in Treating Community Acquired Pneumonia[J].Medical Information,2018,31(08):20.[doi:10.3969/j.issn.1006-1959.2018.02.009]
[2]包克珍,许云丽.新生儿社区获得性肺炎的临床特征分析[J].医学信息,2018,31(02):184.[doi:10.3969/j.issn.1006-1959.2018.02.072]
　BAO Ke-zhen,XU Yun-li.Clinical Characteristics of Neonatal Community Acquired Pneumonia[J].Medical Information,2018,31(08):184.[doi:10.3969/j.issn.1006-1959.2018.02.072]
[3]赵建美,邵 岩,李京津.电脑中频药透对治疗老年社区获得性肺炎的疗效分析[J].医学信息,2018,31(03):146.[doi:10.3969/j.issn.1006-1959.2018.03.052]
　ZHAO Jian-mei,SHAO Yan,LI Jing-jin.Analysis of the Efficacy of Computer Medium Frequency Drug Penetration in the Treatment of Elderly Community-acquired Pneumonia[J].Medical Information,2018,31(08):146.[doi:10.3969/j.issn.1006-1959.2018.03.052]
[4]曹立杰,杨林瀛,于国云,等.N-末端脑钠肽前体与社区获得性肺炎患者严重程度关系研究[J].医学信息,2018,31(04):1.[doi:10.3969/j.issn.1006-1959.2018.04.001]
　CAO Li-jie,YANG Lin-ying,YU Guo-yun,et al.Study on the Relationship between N-terminal Brain Natriuretic Peptide Precursors and the Severity of Community-acquired Pneumonia[J].Medical Information,2018,31(08):1.[doi:10.3969/j.issn.1006-1959.2018.04.001]
[5]武珊珊.喜炎平注射液治疗社区获得性肺炎临床疗效的Meta分析[J].医学信息,2018,31(14):64.[doi:10.3969/j.issn.1006-1959.2018.14.020]
　WU Shan-shan.Meta-analysis of Clinical Efficacy of Xiyanping Injection in the Treatment of Community-acquired Pneumonia[J].Medical Information,2018,31(08):64.[doi:10.3969/j.issn.1006-1959.2018.14.020]
[6]徐安林,刘 忠.不同配比的哌拉西林-他唑巴坦治疗 老年性社区获得性肺炎的疗效对比[J].医学信息,2018,31(15):129.[doi:10.3969/j.issn.1006-1959.2018.15.041]
　XU An-lin,LIU Zhong.Comparison of the Efficacy of Different Ratios of Piperacillin-tazobactam in Elderly Community Acquired Pneumoni[J].Medical Information,2018,31(08):129.[doi:10.3969/j.issn.1006-1959.2018.15.041]
[7]许 俊.慢性阻塞性肺疾病急性加重期与慢性阻塞性肺疾病并发社区获得性肺炎患者的临床对比[J].医学信息,2018,31(22):118.[doi:10.3969/j.issn.1006-1959.2018.22.033]
　XU Jun.Clinical Comparison of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Chronic Obstructive Pulmonary Disease Complicated with Community Acquired Pneumonia[J].Medical Information,2018,31(08):118.[doi:10.3969/j.issn.1006-1959.2018.22.033]
[8]远 颖.成人社区获得性肺炎中医药研究[J].医学信息,2018,31(23):55.[doi:10.3969/j.issn.1006-1959.2018.23.016]
　YUAN Ying.Traditional Chinese Medicine Research on Adult Community Acquired Pneumonia[J].Medical Information,2018,31(08):55.[doi:10.3969/j.issn.1006-1959.2018.23.016]
[9]陈亚南,陈 赛,毛琦善.青壮年与中老年社区获得性肺炎病原体的对比分析[J].医学信息,2019,32(01):145.[doi:10.3969/j.issn.1006-1959.2019.01.045]
　CHEN Ya-nan,CHEN Sai,MAO Qi-shan.Comparative Analysis of Pathogens of Acquired Pneumonia among Young Adults and Middle-aged and Elderly People[J].Medical Information,2019,32(08):145.[doi:10.3969/j.issn.1006-1959.2019.01.045]
[10]刘 岩.利奈唑胺联合莫西沙星治疗结核性脑膜炎的效果[J].医学信息,2019,32(16):131.[doi:10.3969/j.issn.1006-1959.2019.16.043]
　LIU Yan.Effect of Linezolid Combined with Moxifloxacin on Tuberculous Meningitis[J].Medical Information,2019,32(08):131.[doi:10.3969/j.issn.1006-1959.2019.16.043]

更新日期/Last Update: 1900-01-01